StockData
Labcorp Holdings Inc. logo

Labcorp Holdings Inc. (LH) stock

LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/3016% above fair value
$368.24−4.22 (-1.13%)

Close on Nov 17, 2026Market cap $29.90BP/E 30.2Yield 0.78%

Labcorp operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Labcorp's operating income for the twelve months ending Sep 30, 2026 was $1.50B, up 12.6% year over year. For fiscal 2025 it was $1.38B, up 27.4% from the year before. Over ten years it grew 3.3% a year on average. The highest annual figure on record is $3.05B in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.38B+27.4%
FY2024Dec 31, 2024$1.09B+49.8%
FY2023Dec 31, 2023$725.60M-49.5%
FY2022Dec 31, 2022$1.44B-52.9%
FY2021Dec 31, 2021$3.05B+24.7%
FY2020Dec 31, 2020$2.45B+83.8%
FY2019Dec 31, 2019$1.33B+0.3%
FY2018Dec 31, 2018$1.33B+1.6%
FY2017Dec 31, 2017$1.31B+2.7%
FY2016Dec 31, 2016$1.27B+27.5%
FY2015Dec 31, 2015$996.80M+9.5%
FY2014Dec 31, 2014$910.40M-8.1%
FY2013Dec 31, 2013$990.90M-3.2%
FY2012Dec 31, 2012$1.02B+7.9%
FY2011Dec 31, 2011$948.40M-3.1%
FY2010Dec 31, 2010$978.80M+4.6%
FY2009Dec 31, 2009$935.90M+11.0%
FY2008Dec 31, 2008$842.90M+8.5%
FY2007Dec 31, 2007$777.00M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$402.10M+1.4%
Q2 FY2026Jun 30, 2026$451.60M+14.5%
Q1 FY2026Mar 31, 2026$380.80M+16.8%
Q4 FY2025Dec 31, 2025$267.60M+23.6%
Q3 FY2025Sep 30, 2025$396.60M+56.1%
Q2 FY2025Jun 30, 2025$394.50M+33.8%
Q1 FY2025Mar 31, 2025$326.00M+1.5%
Q4 FY2024Dec 31, 2024$216.50M–
Q3 FY2024Sep 30, 2024$254.10M+0.7%
Q2 FY2024Jun 30, 2024$294.80M+10.7%
Q1 FY2024Mar 31, 2024$321.30M-2.6%
Q4 FY2023Dec 31, 2023-$122.80M-530.9%
Q3 FY2023Sep 30, 2023$252.30M-32.5%
Q2 FY2023Jun 30, 2023$266.30M-37.9%
Q1 FY2023Mar 31, 2023$329.80M-52.1%
Q4 FY2022Dec 31, 2022$28.50M-94.5%
Q3 FY2022Sep 30, 2022$374.00M-51.2%
Q2 FY2022Jun 30, 2022$428.80M-39.1%
Q1 FY2022Mar 31, 2022$687.90M-35.0%
Q4 FY2021Dec 31, 2021$519.70M-59.8%
Q3 FY2021Sep 30, 2021$766.90M-26.8%
Q2 FY2021Jun 30, 2021$704.10M+136.5%
Q1 FY2021Mar 31, 2021$1.06B–
Q4 FY2020Dec 31, 2020$1.29B+284.4%
Q3 FY2020Sep 30, 2020$1.05B+208.1%
Q2 FY2020Jun 30, 2020$297.70M-11.3%
Q1 FY2020Mar 31, 2020-$192.60M-160.5%
Q4 FY2019Dec 31, 2019$336.40M+9.3%
Q3 FY2019Sep 30, 2019$339.90M-1.0%
Q2 FY2019Jun 30, 2019$335.70M-9.1%
Q1 FY2019Mar 31, 2019$318.20M+4.2%
Q4 FY2018Dec 31, 2018$307.70M-6.9%
Q3 FY2018Sep 30, 2018$343.40M+5.1%
Q2 FY2018Jun 30, 2018$369.20M+11.9%
Q1 FY2018Mar 31, 2018$305.40M-4.0%
Q4 FY2017Dec 31, 2017$330.60M+17.4%
Q3 FY2017Sep 30, 2017$326.70M–
Q2 FY2017Jun 30, 2017$329.80M–
Q1 FY2017Mar 31, 2017$318.10M–
Q4 FY2016Dec 31, 2016$281.60M–

More Labcorp figures

See a number that looks wrong?